Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation

E. C. Reed, D. H. Shepp, P. S. Dandliker, J. D. Meyers

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Ganciclovir, and acyclic nucleoside with improved activity against cytomegalovirus in vitro, was used to treat 15 marrow transplant patients with symptomatic cytomegalovirus infection of the gastrointestinal tract. Eleven of the 15 had improvement in one or more of their clinical signs or symptoms during treatment. No clinical relapses were observed. Viral excretion from throat, urine and blood stopped at a median of 6 days of treatment, but six patients had recurrence of viral excretion 7-25 days after treatment was stopped. The only toxicity was the development of reversible neutropenia in eight of 15 patients after 10-19 days of treatment. Neutropenia was not related to duration of treatment, plasma drug levels or to the neutrophil count at the beginning of treatment. Although treatment with ganciclovir may be associated with marrow suppression, the serious nature of gastrointestinal infection due to cytomegalovirus in the immunocompromised host, the antiviral effect and the possible clinical improvement observed in vivo, and the lack of other effective treatments justify further controlled studies with this agent in immunocompromised patients with serious cytomegalovirus infection.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalBone marrow transplantation
Volume3
Issue number3
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus Infections
Gastrointestinal Tract
Transplantation
Bone Marrow
Immunocompromised Host
Therapeutics
Neutropenia
Cytomegalovirus
Recurrence
Pharynx
Nucleosides
Signs and Symptoms
Antiviral Agents
Neutrophils
Urine
Transplants
Infection

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation. / Reed, E. C.; Shepp, D. H.; Dandliker, P. S.; Meyers, J. D.

In: Bone marrow transplantation, Vol. 3, No. 3, 01.01.1988, p. 199-206.

Research output: Contribution to journalArticle

@article{84bfecc3d5d84808be7fcb1a5b4a850e,
title = "Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation",
abstract = "Ganciclovir, and acyclic nucleoside with improved activity against cytomegalovirus in vitro, was used to treat 15 marrow transplant patients with symptomatic cytomegalovirus infection of the gastrointestinal tract. Eleven of the 15 had improvement in one or more of their clinical signs or symptoms during treatment. No clinical relapses were observed. Viral excretion from throat, urine and blood stopped at a median of 6 days of treatment, but six patients had recurrence of viral excretion 7-25 days after treatment was stopped. The only toxicity was the development of reversible neutropenia in eight of 15 patients after 10-19 days of treatment. Neutropenia was not related to duration of treatment, plasma drug levels or to the neutrophil count at the beginning of treatment. Although treatment with ganciclovir may be associated with marrow suppression, the serious nature of gastrointestinal infection due to cytomegalovirus in the immunocompromised host, the antiviral effect and the possible clinical improvement observed in vivo, and the lack of other effective treatments justify further controlled studies with this agent in immunocompromised patients with serious cytomegalovirus infection.",
author = "Reed, {E. C.} and Shepp, {D. H.} and Dandliker, {P. S.} and Meyers, {J. D.}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "3",
pages = "199--206",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation

AU - Reed, E. C.

AU - Shepp, D. H.

AU - Dandliker, P. S.

AU - Meyers, J. D.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Ganciclovir, and acyclic nucleoside with improved activity against cytomegalovirus in vitro, was used to treat 15 marrow transplant patients with symptomatic cytomegalovirus infection of the gastrointestinal tract. Eleven of the 15 had improvement in one or more of their clinical signs or symptoms during treatment. No clinical relapses were observed. Viral excretion from throat, urine and blood stopped at a median of 6 days of treatment, but six patients had recurrence of viral excretion 7-25 days after treatment was stopped. The only toxicity was the development of reversible neutropenia in eight of 15 patients after 10-19 days of treatment. Neutropenia was not related to duration of treatment, plasma drug levels or to the neutrophil count at the beginning of treatment. Although treatment with ganciclovir may be associated with marrow suppression, the serious nature of gastrointestinal infection due to cytomegalovirus in the immunocompromised host, the antiviral effect and the possible clinical improvement observed in vivo, and the lack of other effective treatments justify further controlled studies with this agent in immunocompromised patients with serious cytomegalovirus infection.

AB - Ganciclovir, and acyclic nucleoside with improved activity against cytomegalovirus in vitro, was used to treat 15 marrow transplant patients with symptomatic cytomegalovirus infection of the gastrointestinal tract. Eleven of the 15 had improvement in one or more of their clinical signs or symptoms during treatment. No clinical relapses were observed. Viral excretion from throat, urine and blood stopped at a median of 6 days of treatment, but six patients had recurrence of viral excretion 7-25 days after treatment was stopped. The only toxicity was the development of reversible neutropenia in eight of 15 patients after 10-19 days of treatment. Neutropenia was not related to duration of treatment, plasma drug levels or to the neutrophil count at the beginning of treatment. Although treatment with ganciclovir may be associated with marrow suppression, the serious nature of gastrointestinal infection due to cytomegalovirus in the immunocompromised host, the antiviral effect and the possible clinical improvement observed in vivo, and the lack of other effective treatments justify further controlled studies with this agent in immunocompromised patients with serious cytomegalovirus infection.

UR - http://www.scopus.com/inward/record.url?scp=0023910258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023910258&partnerID=8YFLogxK

M3 - Article

C2 - 2844343

AN - SCOPUS:0023910258

VL - 3

SP - 199

EP - 206

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -